Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient

被引：10

作者：

Afshar, Kamyar ^{[1
]}

Rao, A. Purush ^{[1
]}

Patel, Vipul ^{[1
]}

Forrester, Kevin ^{[2
]}

Ganesh, Sivagini ^{[1
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Div Pulm & Crit Care, 2020 Zonal Ave,IRD 723, Los Angeles, CA 90033 USA

[2] Univ Southern Calif, Dept Clin Pharm & Pharmaceut Econ & Policy, Los Angeles, CA 90033 USA

来源：

JOURNAL OF TRANSPLANTATION | 2011年 / 2011卷

关键词：

D O I：

10.1155/2011/919651

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation with an annual incidence rate of 3-5% in lung-transplant recipients. Pathogenesis indicates a strong association with functional overimmunosuppression and EBV infection. Clinical improvement is generally observed with reduction in immunosuppression intensity alone. We present a case of a 24-year-old woman with EBV-associated PTLD following lung transplant where decreasing the immunosuppression improved PTLD but was ineffective against controlling the EBV infection. Foscarnet in combination with immunoglobulins was successfully administered to cause a remission of the EBV infection. This is the second case reported of a persistent EBV infection after reducing immunosuppression levels and evidence of PTLD remission that required foscarnet for EBV infection control.

引用

页数：4

共 9 条

[1] Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient [J].